BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Rhabdomyosarcoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
69 results:

  • 1.
    de Traux de Wardin H; Dermawan JK; Vanoli F; Jiang SC; Singer S; Chi P; Tap W; Wexler LH; Antonescu CR
    JCO Precis Oncol; 2024 Apr; 8():e2300597. PubMed ID: 38603649
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prognostic and predictive biomarkers in paediatric solid tumours.
    Glembocki AI; Somers GR
    Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study.
    Kotowicz B; Dańska-Bidzińska A; Fuksiewicz M; Nasierowska-Guttmejer A; Raczkiewicz D; Gujski M; Piątek S; Bidziński M
    Med Sci Monit; 2023 Dec; 29():e941562. PubMed ID: 38058118
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Cytotoxic Effect of Curcumin in rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling.
    Salucci S; Bavelloni A; Stella AB; Fabbri F; Vannini I; Piazzi M; Volkava K; Scotlandi K; Martinelli G; Faenza I; Blalock W
    Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771452
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.
    Macha SJ; Koneru B; Burrow TA; Zhu C; Savitski D; Rahman RL; Ronaghan CA; Nance J; McCoy K; Eslinger C; Reynolds CP
    Cancer Res; 2022 Sep; 82(18):3345-3358. PubMed ID: 35947641
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.
    Meister MT; Groot Koerkamp MJA; de Souza T; Breunis WB; Frazer-Mendelewska E; Brok M; DeMartino J; Manders F; Calandrini C; Kerstens HHD; Janse A; Dolman MEM; Eising S; Langenberg KPS; van Tuil M; Knops RRG; van Scheltinga ST; Hiemcke-Jiwa LS; Flucke U; Merks JHM; van Noesel MM; Tops BBJ; Hehir-Kwa JY; Kemmeren P; Molenaar JJ; van de Wetering M; van Boxtel R; Drost J; Holstege FCP
    EMBO Mol Med; 2022 Oct; 14(10):e16001. PubMed ID: 35916583
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
    Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
    Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
    Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
    Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications.
    Nakahata K; Simons BW; Pozzo E; Shuck R; Kurenbekova L; Prudowsky Z; Dholakia K; Coarfa C; Patel TD; Donehower LA; Yustein JT
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35174853
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Molecular Profile of a Pituitary rhabdomyosarcoma Arising From a Pituitary Macroadenoma: A Case Report.
    Lu J; Chen L
    Front Endocrinol (Lausanne); 2021; 12():752361. PubMed ID: 34659131
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. SNAI2-Mediated Repression of
    Wang L; Hensch NR; Bondra K; Sreenivas P; Zhao XR; Chen J; Moreno Campos R; Baxi K; Vaseva AV; Sunkel BD; Gryder BE; Pomella S; Stanton BZ; Zheng S; Chen EY; Rota R; Khan J; Houghton PJ; Ignatius MS
    Cancer Res; 2021 Nov; 81(21):5451-5463. PubMed ID: 34462275
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The fate of paratesticular masses: 13 years' experience in a tertiary referral centre.
    Demirel HC; Tokuç E; Eryilmaz OT; Aykanli E; Yavuzsan AH; Ozagari AA; Kirecci SL; Horasanli K
    Aktuelle Urol; 2024 Apr; 55(2):148-153. PubMed ID: 33853159
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
    Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
    Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. rhabdomyosarcoma associated with germline tp53 alteration in children and adolescents: The French experience.
    Pondrom M; Bougeard G; Karanian M; Bonneau-Lagacherie J; Boulanger C; Boutroux H; Briandet C; Chevreau C; Corradini N; Coze C; Defachelles AS; Galmiche-Roland L; Orbach D; Piguet C; Scoazec JY; Vérité C; Willems M; Frebourg T; Minard V; Brugières L
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28486. PubMed ID: 32658383
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Evaluation of Eribulin Combined with Irinotecan for treatment of Pediatric Cancer Xenografts.
    Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
    Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Signaling pathways in rhabdomyosarcoma invasion and metastasis.
    Ramadan F; Fahs A; Ghayad SE; Saab R
    Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Genomic Determinants of Clinical Outcomes in rhabdomyosarcoma.
    Casey DL; Wexler LH; Pitter KL; Samstein RM; Slotkin EK; Wolden SL
    Clin Cancer Res; 2020 Mar; 26(5):1135-1140. PubMed ID: 31699828
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
    Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
    Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Hedgehog signaling negatively co-regulates BH3-only protein Noxa and TAp73 in tp53-mutated cells.
    Meister MT; Boedicker C; Klingebiel T; Fulda S
    Cancer Lett; 2018 Aug; 429():19-28. PubMed ID: 29702195
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway.
    Kleinsimon S; Longmuss E; Rolff J; Jäger S; Eggert A; Delebinski C; Seifert G
    Sci Rep; 2018 Apr; 8(1):5750. PubMed ID: 29636527
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.